Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2020
SIETES contiene 93011 citas

 
 
 1 a 20 de 66 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Ivacaftor et mucoviscidose (suite). Prescrire 2017;37:566-8. [Ref.ID 102040]
2. Cita con resumen
Anónimo. Ivacaftor + lumacaftor et mucoviscidose. Prescrire 2017;37:569-71. [Ref.ID 102039]
3. Cita con resumen
Anónimo. Osimertinib et cancer bronchique avec mutation T790M. Prescrire 2017;37:11-3. [Ref.ID 101360]
4.Tiene citas relacionadas Cita con resumen
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, for the TRAFFIC and TRANSPORT Study Groups. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220-31. [Ref.ID 99349]
5.Tiene citas relacionadas
Davis PB. Another beginning for cystic fibrosis therapy. N Engl J Med 2015;373:274-6. [Ref.ID 99113]
6.Enlace a cita original
Kolata G. A faster way to try many drugs on many cancers. N Y Times (Print) 2015:25 de febrero. [Ref.ID 98846]
7. Cita con resumen
Koenekoop RK, Sui R, Sallum J, van der Born LI, Ajlan R, Khan A, den Hollander AI, Cremers FPM, Mendola JD, Bittner AK, Dagnelie G, Schuchard RA, Saperstein DA. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet 2014;384:1513-20. [Ref.ID 98252]
8. Cita con resumen
Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. A randomized trial. JAMA 2012;307:1383-93. [Ref.ID 92698]
9.Tiene citas relacionadas Cita con resumen
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, on behalf of the MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:2103-14. [Ref.ID 91319]
10.Tiene citas relacionadas
Hewish M, Cunningham D. First-line treatment of advanced colorectal cancer. Lancet 2011;377:206-2062. [Ref.ID 91312]
11. Cita con resumen
12.
Stein RA. Lessons from outbreaks of H1N1 influenza. Ann Intern Med 2009;151:59-62. [Ref.ID 86258]
13.Tiene citas relacionadas
Van Cutsem E, Rougier P, Köhne C-H. Cetuximab for metastatic colorectal cancer. The authors reply. N Engl J Med 2009;361:96-7. [Ref.ID 86194]
14.Tiene citas relacionadas
Garattini S, Torri V, Floriani I. Cetuximab for metastatic colorectal cancer. N Engl J Med 2009;361:96. [Ref.ID 86193]
15.Tiene citas relacionadas
Bria E, Cuppone F, Di Maio M. Cetuximab for metastatic colorectal cancer. N Engl J Med 2009;361:95-6. [Ref.ID 86192]
16.Tiene citas relacionadas
Roila F, Garassino MC, Ballatori E. Cetuximab for metastatic colorectal cancer. N Engl J Med 2009;361:95. [Ref.ID 86191]
17.Tiene citas relacionadas
Spiro H. Cetuximab for metastatic colorectal cancer. N Engl J Med 2009;361:95. [Ref.ID 86190]
18.Tiene citas relacionadas Cita con resumen
Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine?. N Engl J Med 2009;360:1925-7. [Ref.ID 85769]
19.Tiene citas relacionadas Cita con resumen
Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chien C-R, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17. [Ref.ID 85548]
20.Tiene citas relacionadas
Karapetis C, O'Callaghan C, Khambata-Ford S. K-ras mutations and cetuximab in colorectal cancer. The authors reply. N Engl J Med 2009;360:835-6. [Ref.ID 85295]
Seleccionar todas
 
 1 a 20 de 66 siguiente >>